Vor Bio says China NMPA approves telitacicept for Sjögren’s disease

Vor Biopharma

Vor Biopharma

VOR

0.00
  • China’s NMPA cleared telitacicept for adult Sjögren’s disease, marking the first regulatory approval for the indication.
  • RemeGen will develop, secure approvals, commercialize in China; Vor Bio holds rights outside Greater China.
  • Decision was supported by Phase 3 data showing significant ESSDAI reductions at Week 24; improvements in ESSPRI.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.